Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?

• Marco Bernardi,
• Luigi Spadafora,
• Mattia Galli,
• Giuseppe Biondi-Zoccai,
• Pierre Sabouret

Affiliations

Marco Bernardi

Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy

Luigi Spadafora

Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy

Mattia Galli

Catholic University of the Sacred Heart, Rome, Italy

Giuseppe Biondi-Zoccai

Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy

Pierre Sabouret

ORCiD

Heart Institute, 47-83 Boulevard de l’Hôpital, ACTION Study Group-CHU Pitié-Salpétrière Paris, France